8.00
price down icon0.87%   -0.07
after-market 시간 외 거래: 8.00
loading
전일 마감가:
$8.07
열려 있는:
$8.07
하루 거래량:
764.75K
Relative Volume:
0.45
시가총액:
$2.51B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-11.76
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
-2.91%
1개월 성능:
-1.60%
6개월 성능:
-7.83%
1년 성능:
+7.96%
1일 변동 폭
Value
$7.975
$8.07
1주일 범위
Value
$7.79
$8.30
52주 변동 폭
Value
$6.50
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
명칭
Amneal Pharmaceuticals Inc
Name
전화
908-947-3120
Name
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
직원
5,210
Name
트위터
@amnealpharma
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
AMRX's Discussions on Twitter

AMRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
8.00 2.49B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
152.82 68.32B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.66 46.55B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.85 43.80B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.33 19.01B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
306.41 13.79B 2.99B 1.21B 1.13B 25.06

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-06 개시 Goldman Buy
2025-02-24 업그레이드 JP Morgan Neutral → Overweight
2024-09-06 업그레이드 JP Morgan Underweight → Neutral
2021-04-07 재개 RBC Capital Mkts Sector Perform
2021-03-08 업그레이드 Goldman Sell → Buy
2020-12-14 업그레이드 Barclays Equal Weight → Overweight
2020-12-14 업그레이드 Guggenheim Neutral → Buy
2020-07-27 개시 Goldman Sell
2020-05-12 업그레이드 Guggenheim Sell → Neutral
2019-12-12 다운그레이드 Raymond James Outperform → Mkt Perform
2019-11-12 다운그레이드 JP Morgan Neutral → Underweight
2019-11-07 다운그레이드 SVB Leerink Outperform → Mkt Perform
2019-07-22 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-07-11 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-07-08 업그레이드 Piper Jaffray Neutral → Overweight
2019-06-11 개시 Barclays Equal Weight
2019-05-21 업그레이드 Raymond James Mkt Perform → Strong Buy
2019-03-20 개시 SunTrust Buy
2019-03-08 다운그레이드 SVB Leerink Outperform → Mkt Perform
2018-12-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2018-10-16 다운그레이드 SunTrust Buy → Hold
2018-08-13 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2018-07-23 개시 Morgan Stanley Overweight
2018-06-22 개시 B. Riley FBR, Inc. Buy
모두보기

Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스

pulisher
Jul 24, 2025

Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Amneal Pharmaceuticals Prices $600M Senior Notes Offering - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Amneal Pharmaceuticals Inc. stock priceOutstanding trading profits - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Amneal Pharmaceuticals Inc. Stock Analysis and ForecastUnrivaled growth potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Amneal Pharmaceuticals Inc. stockSignificant capital appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire

Jul 22, 2025
pulisher
Jul 21, 2025

Amneal reports 3% revenue growth in Q2, advances deleveraging By Investing.com - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal seeks to borrow $1.8 billion in new term loans, offers notes - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Amneal Pharmaceuticals Unveils Massive $2.55 Billion Debt Restructuring PlanWhat's Changing - Stock Titan

Jul 21, 2025
pulisher
Jul 18, 2025

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.

Jul 18, 2025
pulisher
Jul 16, 2025

Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com

Jul 16, 2025
pulisher
Jul 13, 2025

Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN

Jul 13, 2025
pulisher
Jul 10, 2025

Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire

Jul 10, 2025
pulisher
Jul 09, 2025

Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan

Jul 09, 2025
pulisher
Jul 04, 2025

Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail

Jul 04, 2025
pulisher
Jul 02, 2025

Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance

Jul 02, 2025
pulisher
Jun 30, 2025

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Jun 30, 2025
pulisher
Jun 27, 2025

Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports - insights.citeline.com

Jun 27, 2025
pulisher
Jun 26, 2025

5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - FinancialContent

Jun 26, 2025
pulisher
Jun 25, 2025

Amneal reports positive phase 3 results for XOLAIR biosimilar By Investing.com - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 24, 2025

Amneal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for AMRX - Nasdaq

Jun 24, 2025
pulisher
Jun 19, 2025

Investing in Amneal Pharmaceuticals (NASDAQ:AMRX) three years ago would have delivered you a 157% gain - simplywall.st

Jun 19, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal's prednisolone acetate ophthalmic suspension - Eyes On Eyecare

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Jun 12, 2025

Amneal Pharmaceuticals Inc (AMRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$70.93
price down icon 3.25%
$14.69
price down icon 2.20%
$9.35
price down icon 0.21%
drug_manufacturers_specialty_generic RDY
$14.71
price up icon 0.75%
$131.64
price down icon 1.51%
$306.41
price up icon 0.26%
자본화:     |  볼륨(24시간):